lymphocyte-specific tyrosine kinase inhibitors (Novartis)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Namelymphocyte-specific tyrosine kinase inhibitors (Novartis)
Drug Alias NameLck inhibitors (Novartis)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase LCK inhibitors
TargetsTyrosine-protein kinase LCK
Therapy Area/IndicationsAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwitzerland
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNovartis Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovartis Ag
Active IndicationsN/A
Inactive IndicationsAutoimmune Diseases

Other Information

ATC CodeN/A
Related LinksN/A